Projects per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 4 Finished
-
Adjunct vitamin D therapy as a means to reduce the dispa
WAYNE STATE UNIVERSITY, NATIONAL INSTITUTES OF HEALTH (NIH)
12/1/15 → 6/30/16
Project: Research project
-
Analytical support for Project Phidisa
THE HENRY M. JACKSON FOUNDATION, NATIONAL INSTITUTES OF HEALTH (NIH)
4/1/14 → 9/30/15
Project: Research project
-
Adjunct vitamin D therapy as a means to reduce the dispa
WAYNE STATE UNIVERSITY, NATL INSTITUTE ON MINORITY HEALTH (NIH)
7/1/11 → 11/30/15
Project: Research project
-
Infectious Disease Clinical Research Program - Data Anal
Eberly, L., Grandits, G. A. & Lifson, A. R.
THE HENRY M. JACKSON FOUNDATION, UNIFORMED SVC UNIV OF THE HEALTH SCI
5/23/07 → 3/31/12
Project: Research project
-
Does Vitamin D Provide Added Benefit to Antihypertensive Therapy in Reducing Left Ventricular Hypertrophy Determined by Cardiac Magnetic Resonance?
Levy, P. D., Twiner, M. J., Brody, A. M., Dawood, R., Reed, B., Mango, L. M., Gowland, L., Grandits, G., Svendsen, K., Haacke, E. M., Li, T., Zhang, L., McNaughton, C. D. & Flack, J. M., Jan 1 2023, In: American journal of hypertension. 36, 1, p. 50-62 13 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group, May 2022, In: The Lancet Infectious Diseases. 22, 5, p. 622-635 14 p.Research output: Contribution to journal › Article › peer-review
Open Access111 Scopus citations -
Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group, Sep 15 2022, In: American journal of respiratory and critical care medicine. 206, 6, p. 730-739 10 p.Research output: Contribution to journal › Article › peer-review
Open Access6 Scopus citations -
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial
ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group, Oct 2022, In: The Lancet Respiratory Medicine. 10, 10, p. 972-984 13 p.Research output: Contribution to journal › Article › peer-review
Open Access51 Scopus citations -
Early cardiovascular structural and functional abnormalities as a guide to future morbid events
Duprez, D. A., Duval, S., Hoke, L., Florea, N., Grandits, G., Carlson, C., Lee, J. & Cohn, J. N., Nov 1 2021, In: European Journal of Preventive Cardiology. 28, 11, p. 1214-1221 8 p.Research output: Contribution to journal › Article › peer-review
6 Scopus citations